Relapsed/Refractory Acute Myeloid Leukemia Clinical Trial
Official title:
Expanded Access Program for Magrolimab
| NCT number | NCT05627466 |
| Other study ID # | GS-US-546-6531 |
| Secondary ID | |
| Status | No longer available |
| Phase | |
| First received | |
| Last updated |
| Verified date | February 2024 |
| Source | Gilead Sciences |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Expanded Access |
The goal of this expanded access program is to provide rapid access to magrolimab free-of-cost material, to treat patients in the United States suffering from relapsed or refractory acute myeloid leukemia (AML).
| Status | No longer available |
| Enrollment | 0 |
| Est. completion date | |
| Est. primary completion date | |
| Accepts healthy volunteers | |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Key Inclusion Criteria: - Individuals with confirmation of acute myeloid leukemia (AML) according to WHO 2016 classification who are refractory or relapsed, ineligible for all known drugs with proven efficacy, and ineligible for existing clinical studies; and the treating physician has assessed that the potential benefits of magrolimab outweigh the risks. - Eastern Cooperative Oncology Group performance status score of 0 to 3. - Treating physician plans to administer magrolimab in combination with azacitadine/venetoclax or magrolimab in combination with azacitadine alone, following the indication-specific combinations described in the protocol. Key Exclusion Criteria: - Known hypersensitivity to magrolimab, azacitidine, venetoclax, their metabolites, or formulation excipients, if applicable to planned treatment regimen. - Prior treatment with cluster of differentiation (CD)47 or signal regulatory protein alpha (SIRPa)-targeting agents. Note: Other protocol defined Inclusion/Exclusion criteria may apply. |
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| Gilead Sciences |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05731219 -
UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 1 | |
| Recruiting |
NCT05061147 -
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05548088 -
LILRB4 STAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 1 | |
| Terminated |
NCT03504410 -
Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AML
|
Phase 3 | |
| Enrolling by invitation |
NCT05332054 -
Long-Term Follow-up Study
|
||
| Withdrawn |
NCT03904069 -
Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML
|
Phase 1 | |
| Completed |
NCT05518357 -
LILRB4 STAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 1 | |
| Recruiting |
NCT03190278 -
Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 1 | |
| Completed |
NCT02665143 -
A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia
|
Phase 2 | |
| Completed |
NCT03886831 -
A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies
|
Phase 1 | |
| Recruiting |
NCT05722171 -
Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
|
Early Phase 1 | |
| Completed |
NCT03318016 -
Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 1 | |
| Recruiting |
NCT06084819 -
Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 2 |